Therefore, established mouse models employed in human TNFα antagonist development—such as hTNFα transgenic arthritis model, DSS-induced colitis model, and collagen-induced arthritis model—could provide valuable preliminary platforms for assessing minibinder efficacy against cTNFα, particularly when incorporated with species-specific affinity data. This evidence concerns the gene TNF and colitis.